Aug 22, 2017 4:30 pm EDT Volition Signs Agreement with the Institute of Laboratory Medicine of the Technical University of Munich, Germany, to assist in securing large trials in a range of cancers
Aug 9, 2017 4:05 pm EDT VolitionRx Limited Announces Second Quarter 2017 Financial Results and Business Update
Aug 3, 2017 4:30 pm EDT VolitionRx Limited Schedules Second Quarter 2017 Earnings Conference Call and Business Update
Jul 19, 2017 4:30 pm EDT VolitionRx Limited to host a conference call regarding a 13,500 Subject Colorectal Cancer Screening Trial with the Early Detection Research Network of the U.S. National Cancer Institute
Jul 18, 2017 6:30 am EDT Volition America, Inc. Announces a Colorectal Cancer Screening Trial containing approximately 13,500 Subjects in Collaboration with the Early Detection Research Network of the U.S. National Cancer Institute
Jun 30, 2017 9:22 am EDT Volition to Present at the EuropaColon Advocacy Masterclass and Exhibit at the European Society for Medical Oncology Gastrointestinal Cancer Congress
May 18, 2017 9:00 am EDT A new publication reports that 91% of colorectal cancers were detected at 90% specificity in a completed prospective trial using Volition's Nu.Q(TM) assays
May 11, 2017 6:30 am EDT VolitionRx Limited Announces First Quarter 2017 Financial Results and Business Update
